Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy is increasingly being used both pre-operatively (neoadjuvant chemotherapy) and post-operatively (adjuvant chemotherapy).
We researched this topic for you and found the following best online resources. They are categorized into basic, advanced, and research level based on the extent of information you need. You will be taken to the respective websites by pressing on the links below.
Basic information:
http://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq cancer.gov non-small-cell lung cancer
https://www.nlm.nih.gov/medlineplus/ency/article/007194.htm medline plus lung cancer - non-small cell
http://www.webmd.com/lung-cancer/guide/non-small-cell-lung-cancer web md non-small-cell lung cancer
http://umm.edu/health/medical/reports/articles/nonsmall-cell-lung-cancer university of maryland medical center non-small-cell lung cancer
http://www.healthline.com/health/lung-cancer-non-small-cell health line non-small cell lung cancer
http://my.clevelandclinic.org/health/diseases_conditions/hic_lung_cancer/hic_non-small_cell_lung_cancer cleveland clinic non-small cell lung cancer
Advanced information:
http://emedicine.medscape.com/article/279960-overview medscape non-small cell lung cancer
http://emedicine.medscape.com/article/279960-treatment medscape non-small cell lung cancer treatment & management
http://www.lungcancer.org/find_information/publications/163-lung_cancer_101/268-types_and_staging lung cancer.org types and staging of lung cancer
http://www.esmo.org/guidelines/lung-and-chest-tumours/metastatic-non-small-cell-lung-cancer metastatic non-small-cell lung cancer: esmo clinical practice guidelines by m. reck, s. popat, n. reinmuth, d. de ruysscher, k. m. kerr, s. peters ann oncol (2014) 25 (suppl 3): iii27-iii39.
society of nuclear medicine. "fdg pet evaluates immunotherapy for non-small cell lung cancer: molecular imaging is used to monitor a novel immunotherapy that aims to hamper tumors' ability to turn off cancer-fighting immune cells." sciencedaily. sciencedaily, 13 june 2016. www.sciencedaily.com/releases/2016/06/160613165025.htm .
http://www.genome.jp/kegg-bin/show_pathway?hsa05223 keg pathway non-small cell lung cancer - homo sapiens (human)
http://www.uptodate.com/contents/non-small-cell-lung-cancer-treatment-stage-i-to-iii-cancer-beyond-the-basics upto date patient information: non-small cell lung cancer treatment; stage i to iii cancer (beyond the basics)
Research:
http://europepmc.org/backend/ptpmcrender.fcgi?accid=pmc3306389&blobtype=pdf : kuo c-h, lo c-y, chung f-t, lee k-y, lin s-m, et al. (2012) concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country. plos one 7(3): e33226. doi:10.1371/journal.pone.0033226
http://europepmc.org/backend/ptpmcrender.fcgi?accid=pmc4408055&blobtype=pdf zhu l, yu h, liu s-y, xiao x-s, dong w-h,chen y-n, et al. (2015) prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non–small cell lung cancer: a systematic review and meta-analysis. plos one 10(4): e0124230. doi:10.1371/journal.pone.0124230
http://journal.frontiersin.org/article/10.3389/fonc.2014.00182/full mini review article front. oncol., 16 july 2014 | http://dx.doi.org/10.3389/fonc.2014.00182 non-small cell lung carcinoma biomarker testing: the pathologist’s perspective by elisa brega and guilherme brandao
http://web.imu.edu.my/ejournal/approved/ejournal_2.2_23-26.pdf pet-ct imaging in non-small cell lung carcinoma – a review of cases from a northern malaysia referral centre by joni bing fei teoh et al., iejsme 2008: 2 (2): 23-26
http://europepmc.org/backend/ptpmcrender.fcgi?accid=pmc4783083&blobtype=pdf : hu x, pu k, feng x, wen s, fu x, guo c,et al. (2016) role of gemcitabine and pemetrexed as maintenance therapy in advanced nsclc:a systematic review and meta-analysis of randomized controlled trials. plos one 11(3):e0149247. doi:10.1371/journal.pone.0149247
desai c, mehta a, mishra d. usage patterns of biomarkers in non-small-cell lung cancer patients in india: findings from a systematic review and survey. lung india [serial online] 2014 [cited 2016 jul 1];31:249-59. available from: http://www.lungindia.com/text.asp?2014/31/3/249/135767
http://www.nejm.org/doi/full/10.1056/nejmoa060096#t=article a five-gene signature and clinical outcome in non–small-cell lung cancer by hsuan-yu chen, m.sc et al., n engl j med 2007; 356:11-20january 4, 2007doi: 10.1056/nejmoa060096
http://oncology.jamanetwork.com/article.aspx?articleid=2513900 prognostic and predictive value in kras in non–small-cell lung cancera review by kevin wood, md jama oncol. 2016;2(6):805-812. doi:10.1001/jamaoncol.2016.0405.
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0246-5 emerging roles of nrf2 signal in non-small cell lung cancer by yijun tian et al., journal of hematology & oncology20169:14 doi: 10.1186/s13045-016-0246-5
http://err.ersjournals.com/content/22/127/33 nonsmall cell lung cancer by jean-paul sculier european respiratory review 2013 22: 33-36; doi: 10.1183/09059180.00007012
http://www.omicsonline.org/tp53-is-a-mutational-target-in-non-small-cell-lung-cancer-patients-2157-2518.1000138.php?aid=11703 alpana s, javid j, mir r, masroor m, ahamad i, et al. (2013) tp53 is a mutational target in non small cell lung cancer patients and its pro/pro variant is potentially contributing to cancer susceptibility. j carcinogene mutagene 4:138. doi: 10.4172/2157-2518.1000138
http://medind.nic.in/iae/t04/i3/iaet04i3p191.pdf non small cell lung cancer (nsclc): current status and future prospects by a.k. pathak, m. bhutani et al., indian j chest dis allied sci 2004; 46 : 191-203
http://www.atsjournals.org/doi/full/10.1513/pats.200809-107lc#.v4tsldkuesq gregory j. riely, jenifer marks, and william pao "kras mutations in non–small cell lung cancer", proceedings of the american thoracic society, vol. 6, no. 2 (2009), pp. 201-205.
Related videos:
https://www.youtube.com/watch?v=j5ufbv18bis the pathophysiology of non-small cell lung cancer
https://www.youtube.com/watch?v=iwozzqa3l7c lung cancer staging non-small cell
https://www.youtube.com/watch?v=8kqvbfq0yzo lung cancer (small cell lung carcinoma and non-small cell lung carcinoma) for usmle 2
https://www.youtube.com/watch?v=lvtgdmxzxje non small cell lung cancer overview
https://www.youtube.com/watch?v=rtn712ukew8 the role of immunotherapy in non small cell lung cancer nsclc
https://www.youtube.com/watch?v=qdfwqhtylvq nivolumab in non-small cell lung cancer
https://www.youtube.com/watch?v=zpitrq9gzaa vats lobectomy for the treatment of non-small cell lung cancer
Presentations/quiz/newspaper articles:
http://www.medgadget.com/2016/07/lung-cancer-therapeutics-market-development-size-share-growth-and-demand-forecast-to-2015-2021.html medgadget lung cancer therapeutics market : development, size, share, growth and demand forecast to 2015 – 2021
http://www.dailyrecord.co.uk/news/scottish-news/first-new-lung-cancer-drugs-8401818#qy94zmc7i4jdkloj.97 daily record first new lung cancer drugs in 20 years approved for use in scotland
read more at http://www.dailyrecord.co.uk/news/scottish-news/first-new-lung-cancer-drugs-8401818#ecuxtewwcwx4iu2y.99
http://www.scotsman.com/news/lung-cancer-treatments-approved-for-scottish-nhs-1-4174751 the scotsman lung cancer treatments approved for scottish nhs